Blau Farmacêutica (BLAU3) investor relations material

Executive summary

• Net revenue reached BRL 435 million in Q1 2026, growing between 17% and 33% year-over-year, driven by strong hospital segment performance, federal bidding, and resilient demand for mature products.

• Gross margin expanded to 41.4%, up 130 bps year-over-year, reflecting efficiency gains and favorable currency effects.

• Recurring EBITDA margin reached 23.9%, up 170 bps year-over-year, with recurring EBITDA at BRL 104 million, up 25%.

• Recurring net income was BRL 36 million; excluding exchange rate impacts, recurring net income was BRL 58 million, up 8% year-over-year.

• Zero leverage and a net cash position exceeding debt by BRL 15 million provide flexibility for ongoing investments.

Financial highlights

• Hospital segment revenue grew 18% year-over-year, driven by federal bids and mature products.

• Launches increased 32-33% year-over-year, now representing up to 7.6% of total revenue.

• Gross profit margin improved due to better capacity utilization, cost dilution, and operational efficiency.

• Expenses grew in line with revenue, with no dilution in Q1 due to prior investments in teams.

• Working capital cycle impacted by supplier financing and inventory build-up, expected to normalize during the year.

Outlook and guidance

• New production lines and launches, especially monoclonal antibodies, are expected to drive revenue growth through 2026, with significant impact in 2027.

• Pipeline of drugs in ANVISA queue with a BRL 2.7 billion addressable market; launches expected to accelerate as approvals come through.

• Company aims to more than double its addressable market in three years, with further growth after launching four monoclonal antibodies.

• EBITDA margin expected to improve by 100-200 bps in 2026 as operational leverage increases and expense dilution occurs.

• Investment pace to accelerate, especially in clinical studies and innovation.